NeoGenomics’ RaDaR ST Molecular Residual Disease Assay Receives Expanded Coverage From CMS’ MolDX To Include Immunotherapy Monitoring For Patients With Late-Stage Solid Tumors

NeoGenomics, Inc.

NeoGenomics, Inc.

NEO

0.00

New coverage extends RaDaR ST to patients with advanced cancer on immunotherapy, expanding MRD testing across the cancer care continuum

NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, announced that its RaDaR® ST molecular residual disease (MRD) assay has received expanded coverage from the Centers for Medicare & Medicaid Services' (CMS) Molecular Diagnostic Services Program (MolDX) to include immunotherapy monitoring for patients with late-stage solid tumors.

Medicare coverage for RaDaR ST now includes monitoring of response to immune-checkpoint inhibitor therapy in patients with late-stage solid tumors.1 This is the third Medicare-covered indication for RaDaR ST, which also includes HPV-negative head and neck squamous cell carcinoma and a subset of hormone receptor-positive (HR+), HER2-negative breast cancer. NeoGenomics also has two additional RaDaR ST submissions pending with MolDX.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.